← 返回前沿论文

用于多发性骨髓瘤的单 VHH 导向 BCMA CAR-NK 细胞

英文原题:Single VHH-directed BCMA CAR-NK cells for multiple myeloma.

PubMed 2023/11/27(内容时间) Exp Hematol Oncol Q1 · IF 17.5(JCR 2025)

研究概要

这些结果表明,单一 VHH 导向的 BCMA CAR-NK 细胞表现出显著的特异性杀伤能力,使其成为多发性骨髓瘤治疗中免疫治疗的潜在候选。

中文摘要

自然杀伤(NK)细胞是制备“现货型”CAR产品的有前景替代来源,其细胞因子释放综合征(CRS)风险低于CAR-T细胞。我们合成了4种由单个VHH结构域介导靶向的抗BCMA CAR,分别采用不同胞内结构域(2B4或CD28)和铰链结构域(CD28或IgG1),并异位表达IL-15。使用K562-mbIL21饲养细胞在体外扩增外周血(PB)来源NK细胞;随后以BaEV-Rless假病毒包膜慢病毒载体实现稳定CAR转导。异位表达IL-15的BCMA-CD28-IL15 CAR-NK细胞,与缺少IL-15的BCMA-CD28 CAR-NK及具有IgG1铰链结构域的BCMA-hIgG1-IL15 CAR-NK相比,显示出更强细胞毒性。我们还评估了具有2B4胞内结构域的BCMA-2B4-IL15 CAR-NK细胞的细胞毒能力。体外实验中,BCMA-CD28-IL15 CAR-NK对BCMA阳性肿瘤细胞的细胞毒作用更强、细胞因子分泌更多,优于BCMA-2B4-IL15 CAR-NK。在MM.1S-Luc小鼠模型中,BCMA-CD28-IL15 CAR-NK抑制肿瘤细胞生长并延长小鼠生存。这些结果表明,单VHH靶向的BCMA CAR-NK具有显著的特异性杀伤能力,是治疗多发性骨髓瘤的潜在免疫疗法候选。

展开英文摘要原文

Natural killer (NK) cells are promising alternatives for the production of "off-the-shelf" CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-directed anti-BCMA CARs, incorporating various intracellular regions (2B4 versus CD28) and hinge domains (CD28 versus IgG1) and ectopically producing IL-15. NK cells derived from peripheral blood (PB) were expanded ex vivo by K562-mbIL21 feeder cells. Stable CAR transduction was obtained through lentiviral transduction with the BaEV-Rless pseudotyped lentiviral vector. BCMA-CD28-IL15 CAR-NK cells with ectopic expression of IL-15 exhibited superior cytotoxicity were compared to BCMA-CD28 CAR-NK cells lacking IL-15 and BCMA-hIgG1-IL15 CAR-NK cells with an IgG1 hinge domain. We further assessed the cytotoxic capabilities of BCMA-2B4-IL15 CAR-NK cells with 2B4 intracellular domain. The BCMA-CD28-IL15 CAR-NK cells revealed stronger cytotoxicity and higher cytokine secretion against BCMA + tumor cells than BCMA-2B4-IL15 CAR-NK cells in vitro. In the MM.1S-Luc mouse model, BCMA-CD28-IL15 CAR-NK inhibited the growth of tumor cells and prolonged mouse survival. These results show that the single VHH-directed BCMA CAR-NK cells exhibited remarkable specific killing ability, making them a potential candidate for immunotherapy in multiple myeloma treatment.

论文信息

作者
Ren Q、Zu Y、Su H、Lu Q、Xiang B、Luo Y、Zhang J、Song Y
第一作者单位
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, 450008, China.China
通讯作者单位
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, 450008, China. songyp@zzu.edu.cn.China
文献类型
读者来信
期刊
Experimental hematology & oncology2023 Nov 27
原文标识
PubMed 38012722 · DOI 10.1186/s40164-023-00461-8